Drug Profile
Apitolisib - Roche
Alternative Names: G-038390; G-038390.1; GDC-0980; GDC-0980.1; RG-7422Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech; Piramed
- Developer Genentech
- Class Amines; Antineoplastics; Heterocyclic bicyclo compounds; Ketones; Morpholines; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Endometrial cancer; Non-Hodgkin's lymphoma; Prostate cancer; Renal cancer; Solid tumours
Most Recent Events
- 01 Apr 2016 Genentech completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, France, Germany, Hong Kong, Israel, Italy, South Korea, Malaysia, Mexico, New Zealand, Peru, Russia, Singapore, Spain, Thailand and the UK (NCT01437566)
- 01 Jun 2015 Genentech completes a phase II trial in Renal cancer (Metastatic disease, Second-line therapy or greater) in USA, France, United Kingdom, Germany and Spain (NCT01442090)
- 01 Nov 2014 Genentech completes a phase I trial in Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater) in USA and United Kingdom (NCT00854152)